Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies

Japanese Journal of Clinical Immunology

Volumn 40, Issue 1, 2017, Pages 68-77

  Kato, Daiki ^a,b   Yaguchi, Tomonori ^a   Iwata, Takashi ^a   Morii, Kenji ^a   Nakagawa, Takayuki ^b   Nishimura, Ryohei ^b   Kawakami, Yutaka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adoptive cell therapy; Chimeric antigen receptor transduced T (CAR T) cell therapy; Immune checkpoint blockade therapy; Tumor immunology; Tumor microenvironment

Indexed keywords

BETA CATENIN; CARBONATE DEHYDRATASE IX; CARCINOEMBRYONIC ANTIGEN; CD19 ANTIGEN; CD4 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CXCL1 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; HLA A2 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MELAN A; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; WNT PROTEIN; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CELL THERAPY; CLINICAL TRIAL (TOPIC); DOWN REGULATION; GENE OVEREXPRESSION; GENETIC ENGINEERING; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; SOLID MALIGNANT NEOPLASM; SYNOVIAL SARCOMA; TH1 CELL; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; BIOLOGICAL THERAPY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; PROTEIN ENGINEERING; TRENDS;

CELL- AND TISSUE-BASED THERAPY; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 85019566250     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.40.68     Document Type: Article

References (82)

1. Kawakami, Y., et al.: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Immunology. 91: 3515-3519, 1994.
2. Kawakami, Y., et al.: Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother. 23: 17-27, 2000.
3. Tran, E., et al.: Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 350: 1387-1390, 2015.
4. Galon, J., et al.: Validation of the Immunoscore (IM). as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients. J Clin Oncol. 34 (Suppl.): abstr 3500, 2016.
5. Mokyr, M.B., et al.: Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy- treated tumor-bearing mice. Cancer Res. 58: 5301-5304, 1998.
6. Iwai, Y., et al.: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99: 12293-12297, 2002.
7. Hodi, F.S., et al.: Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 363: 711-723, 2010.
8. Topalian, S.L., et al.: Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med. 366: 2443-2454, 2012.
9. Brahmer, J., et al.: Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 373: 123-135, 2015.
10. Motzer, R.J., et al.: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 373: 1803-1813, 2015.
11. Powles, T., et al.: MPDL3280A (anti-PD-L1). treatment leads to clinical activity in metastatic bladder cancer. Nature. 515: 558-562, 2014.
12. Hamanishi, J., et al.: Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol. 33: 4015-4022, 2015.
13. Gibson, J.: Anti-PD-L1 for metastatic triple-negative breast cancer. Lancet Oncol. 16: e264, 2015.
14. Muro, K., et al.: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE- 012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 17: 717-726, 2016.
15. Ansell, S.M., et al.: PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. N Engl J Med. 372: 311-319, 2015.
16. Le, D.T., et al.: PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 372: 2509-2520, 2015.
17. Rizvi, N.A., et al.: Cancer Immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 348: 124-128, 2015.
18. Snyder, A., et al.: Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N Engl J Med. 371: 2189-2199, 2014.
19. Tumeh, P.C., et al.: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515: 568-571, 2014.
20. Rosenberg, S.A., Restifo, N.P.: Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 348: 62-68, 2015.
21. Stevanović, S., et al.: Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 33: 1543-1550, 2015.
22. Rosenberg, S.A., et al.: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17: 4550-4557, 2011.
23. Singh, H., et al.: Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther. 22: 95-100, 2015.
24. Kantoff, P.W., et al.: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363: 411-422, 2010.
25. Ahmadi, M., et al.: CD3 limits the efficacy of TCR gene therapy in vivo. Blood. 118: 3528-3537, 2011.
26. Morgan, R.A., et al.: Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science. 314: 126-129, 2006.
27. Johnson, L.A., et al.: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 114: 535-546, 2009.
28. Robbins, P.F., et al.: A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 21: 1019-1027, 2015.
29. Robbins, P.F., et al.: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 29: 917-924, 2011.
30. Cameron, B.J., et al.: Identification of a Titinderived HLA-A1-presented peptide as a crossreactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 5: 197ra103, 2013.
31. Linette, G.P., et al.: Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 122: 863-871, 2013.
32. Rosenberg, S.A., et al.: Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother. 26: 385-393, 2003.
33. Gross, G., et al.: Expression of immunoglobulin- T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 86: 10024-10028, 1989.
34. Lamers, C.H.J., et al.: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 24: e20-22, 2006.
35. Hollyman, D., et al.: Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 32: 169-180, 2009.
36. Morsut, L., et al.: Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell. 164: 780-791, 2016.
37. Wu, C.-Y., et al.: Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 350: aab4077-aab4077, 2015.
38. Zhong, X.-S., et al.: Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 18: 413-420, 2010.
39. Zhao, Y., et al.: A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 183: 5563-5574, 2009.
40. Milone, M.C., et al.: Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. Mol Ther. 17: 1453-1464, 2009.
41. Kochenderfer, J.N., et al.: Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 116: 4099-4102, 2010.
42. Porter, D.L., et al.: Chimeric Antigen Receptor- Modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med. 365: 725-733, 2011.
43. Grupp, S.A., et al.: Chimeric Antigen Receptor- Modified T Cells for Acute Lymphoid Leukemia. N Engl J Med. 368: 1509-1518, 2013.
44. Maude, S.L., et al.: Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 371: 1507-1517, 2014.
45. Porter, D.L., et al.: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 7: 303ra139, 2015.
46. Lee, D.W., et al.: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 385: 517-528, 2015.
47. Louis, C.U., et al.: Antitumor activity and longterm fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 118: 6050-6056, 2011.
48. Park, J.R., et al.: Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 15: 825-833, 2007.
49. Morgan, R.A., et al.: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18: 843-851, 2010.
50. Ahmed, N., et al.: Human Epidermal Growth Factor Receptor 2 (HER2)-Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 33: 1688-1696, 2015.
51. Parkhurst, M.R., et al.: T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 19: 620-626, 2011.
52. Beatty, G.L., et al.: Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2: 112-120, 2014.
53. Yaguchi, T., et al.: The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol. 93: 294-300, 2011.
54. Yaguchi, T., Kawakami, Y.: Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int Immunol. 28: 393-399, 2016.
55. Spranger, S., et al.: Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 523: 231-235, 2015.
56. Yaguchi, T., et al.: Immune suppression and resistance mediated by constitutive activation of Wnt/ β-catenin signaling in human melanoma cells. J Immunol. 189: 2110-2117, 2012.
57. Sumimoto, H., et al.: The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med. 203: 1651-1656, 2006.
58. Sumimoto, H., et al.: Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene. 23: 6031-6039, 2004.
59. Iwata-Kajihara, T., et al.: Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J Immunol. 187: 27-36, 2011.
60. Nishio, H., et al.: Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor. Br J Cancer. 110: 2965-2974, 2014.
61. Ko, J.S., et al.: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 15: 2148-2157, 2009.
62. Koya, R.C., et al.: BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 72: 3928-3937, 2012.
63. Matsuzaki, J., et al.: Tumor-infiltrating NY-ESO-1- specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 107: 7875-7880, 2010.
64. Fourcade, J., et al.: Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 207: 2175-2186, 2010.
65. Inozume, T., et al.: Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. J Invest Dermatol. 136: 255-263, 2016.
66. Sampson, J.H., et al.: EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 20: 972-984, 2014.
67. Fridman, W.H., et al.: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 12: 298-306, 2012.
68. Mattes, J., et al.: Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med. 197: 387-393, 2003.
69. Nishimura, T., et al.: Distinct role of antigenspecific T helper type 1 (Th1). and Th2 cells in tumor eradication in vivo. J Exp Med. 190: 617-627, 1999.
70. Kim, H.-J., Cantor, H.: CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res. 2: 91-98, 2014.
71. Corthay, A., et al.: Primary antitumor immune response mediated by CD4+ T cells. Immunity. 22: 371-383, 2005.
72. Nishimura, T., et al.: The critical role of Th1- dominant immunity in tumor Immunology. Cancer Chemother Pharmacol. 46: S52-61, 2000.
73. Tran, E., et al.: Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 344: 641-645, 2014.
74. Hunder, N.N., et al.: Treatment of metastatic melanoma with autologous CD4+ T cells against NYESO-1. N Engl J Med. 358: 2698-2703, 2008.
75. Bettelli, E., et al.: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 441: 235-238, 2006.
76. Zou, W., Restifo, N.P.: T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 10: 248-256, 2010.
77. Martin-Orozco, N., et al.: T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity. Immunity. 31: 787-798, 2009.
78. Muranski, P., et al.: Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 112: 362-373, 2008.
79. Purwar, R., et al.: Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med. 18: 1248-1253, 2012.
80. Lu, Y., et al.: Th9 cells promote antitumor immune responses in vivo. J Clin Invest. 122: 4160-4171, 2012.
81. Li, Y., et al.: IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol. 175: 2261-2269, 2005.
82. Kawakami, Y., et al.: Development of personalized combination cancer immunotherapy based on the patients’ immune status. Tsukasa Seya., et al. eds. Inflamamtion and immunity in cancer, Springer, pp255-266, 2015.